儿童膜增生性肾小球肾炎的研究进展

摘要

Membranoproliferative glomerulonephritis(MPGN)is immune pathological diagnosis,and it has all sorts of clinical manifestations,poor prognosis and high case fatality rate.The latest classification of MPGN is divided into immunecomplex-mediated and complement-mediated.On the basis of the potential patho-physiology,its related causes can be assessed in order to choose a more appropriate treatment method.Long alter-nate day glucocorticoid-therapy is beneficial to idiopathic MPGN in children.Biological agents used in the treat-ment of MPGN has made great progresses.%膜增生性肾小球肾炎(membranoproliferative glomerulonephritis,MPGN)为免疫病理诊断,其临床表现多样,预后差且病死率高。根据其发病机制的不同,目前最新的分类方法是将 MPGN 分为免疫复合物介导型和补体介导型。根据分类按照可能潜在的病理生理学过程进行相关的病因评估将有助于为MPGN 患者选择更适当的治疗方法。对儿童特发性 MPGN 长期隔日应用糖皮质激素治疗是有益的,生物制剂用于治疗 MPGN 已取得了很大的进展。